Functions and mechanisms of N6‑methyladenosine in prostate cancer (Review)
- Authors:
- Hongyuan Wan
- Yanyan Feng
- Junjie Wu
- Lijie Zhu
- Yuanyuan Mi
-
Affiliations: Wuxi Medical College, Jiangnan University, Wuxi, Jiangsu 214122, P.R. China, Department of Burns and Plastic Surgery, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214122, P.R. China, Department of Urology, The Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214122, P.R. China - Published online on: July 19, 2022 https://doi.org/10.3892/mmr.2022.12796
- Article Number: 280
-
Copyright: © Wan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Sugiura M, Sato H, Kanesaka M, Imamura Y, Sakamoto S, Ichikawa T and Kaneda A: Epigenetic modifications in prostate cancer. Int J Urol. 28:140–149. 2021. View Article : Google Scholar : PubMed/NCBI | |
Wang G, Zhao D, Spring DJ and DePinho RA: Genetics and biology of prostate cancer. Genes Dev. 32:1105–1140. 2018. View Article : Google Scholar : PubMed/NCBI | |
Lobo J, Barros-Silva D, Henrique R and Jerónimo C: The emerging role of epitranscriptomics in cancer: Focus on urological tumors. Genes (Basel). 9:5522018. View Article : Google Scholar : PubMed/NCBI | |
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, Gillessen S, Van der Kwast T and Bristow RG: Prostate cancer. Nat Rev Dis Primers. 7:92021. View Article : Google Scholar : PubMed/NCBI | |
Kimura T, Sato S, Takahashi H and Egawa S: Global trends of latent prostate cancer in autopsy studies. Cancers (Basel). 13:3592021. View Article : Google Scholar : PubMed/NCBI | |
Maitland NJ: Resistance to antiandrogens in prostate cancer: Is it inevitable, intrinsic or induced? Cancers (Basel). 13:3272021. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y and Xu C: Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 178:239–261. 2021. View Article : Google Scholar : PubMed/NCBI | |
Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, et al: Advanced prostate cancer: AUA/ASTRO/SUO guideline PART I. J Urol. 205:14–21. 2021. View Article : Google Scholar : PubMed/NCBI | |
Borque-Fernando A, Espilez R, Miramar D, Corbatón D, Rodríguez A, Castro E, Mateo J, Rello L, Méndez A and Gil Sanz MJ: Genetic counseling in prostate cancer: How to implement it in daily clinical practice? Actas Urol Esp (Engl Ed). 45:8–20. 2021.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI | |
Nowacka-Zawisza M and Wiśnik E: DNA methylation and histone modifications as epigenetic regulation in prostate cancer (review). Oncol Rep. 38:2587–2596. 2017. View Article : Google Scholar : PubMed/NCBI | |
Cimadamore A, Gasparrini S, Scarpelli M, Doria A, Mazzucchelli R, Massari F, Cheng L, Lopez-Beltran A and Montironi R: Epigenetic Modifications and modulators in prostate cancer. Crit Rev Oncog. 22:439–450. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wang YN, Yu CY and Jin HZ: RNA N(6)-methyladenosine modifications and the immune response. J Immunol Res. 2020:63276142020.PubMed/NCBI | |
Desrosiers R, Friderici K and Rottman F: Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci USA. 71:3971–3975. 1974. View Article : Google Scholar : PubMed/NCBI | |
Perry RP, Kelley DE, Friderici K and Rottman F: The methylated constituents of L cell messenger RNA: Evidence for an unusual cluster at the 5′ terminus. Cell. 4:387–394. 1975. View Article : Google Scholar : PubMed/NCBI | |
Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE and Jaffrey SR: Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop codons. Cell. 149:1635–1646. 2012. View Article : Google Scholar : PubMed/NCBI | |
Liang Z, Kidwell RL, Deng H and Xie Q: Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer. Cancer Biol Med. 17:9–19. 2020. View Article : Google Scholar : PubMed/NCBI | |
Yang Z, Wang T, Wu D, Min Z, Tan J and Yu B: RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer. J Exp Clin Cancer Res. 39:2032020. View Article : Google Scholar : PubMed/NCBI | |
Cui H, Wang Y, Li F, He G, Jiang Z, Gang X and Wang G: Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: An updated systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 24:15–23. 2021. View Article : Google Scholar : PubMed/NCBI | |
Chen X, Xu M, Xu X, Zeng K, Liu X, Pan B, Li C, Sun L, Qin J, Xu T, et al: METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer. Mol Cancer. 19:1062020. View Article : Google Scholar : PubMed/NCBI | |
Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, Wang Y, Li X, Xiong XF, Wei B, et al: RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol Cancer. 18:462019. View Article : Google Scholar : PubMed/NCBI | |
Wu Q, Xie X, Huang Y, Meng S, Li Y, Wang H and Hu Y: N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer. J Cancer. 12:682–692. 2021. View Article : Google Scholar : PubMed/NCBI | |
Ji G, Huang C, He S, Gong Y, Song G, Li X and Zhou L: Comprehensive analysis of m6A regulators prognostic value in prostate cancer. Aging (Albany NY). 12:14863–14884. 2020. View Article : Google Scholar : PubMed/NCBI | |
Somasekharan SP, Saxena N, Zhang F, Beraldi E, Huang JN, Gentle C, Fazli L, Thi M, Sorensen PH and Gleave M: Regulation of AR mRNA translation in response to acute AR pathway inhibition. Nucleic Acids Res. 50:1069–1091. 2022. View Article : Google Scholar : PubMed/NCBI | |
Wood S, Willbanks A and Cheng JX: The role of RNA modifications and RNA-modifying proteins in cancer therapy and drug resistance. Curr Cancer Drug Targets. 21:326–352. 2021. View Article : Google Scholar : PubMed/NCBI | |
Nombela P, Miguel-López B and Blanco S: The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities. Mol Cancer. 20:182021. View Article : Google Scholar : PubMed/NCBI | |
Barbieri I and Kouzarides T: Role of RNA modifications in cancer. Nat Rev Cancer. 20:303–322. 2020. View Article : Google Scholar : PubMed/NCBI | |
Liu Z, Zhong J, Zeng J, Duan X, Lu J, Sun X, Liu Q, Liang Y, Lin Z, Zhong W, et al: Characterization of the m6A-Associated tumor immune microenvironment in prostate cancer to aid immunotherapy. Front Immunol. 12:7351702021. View Article : Google Scholar : PubMed/NCBI | |
Schöller E, Weichmann F, Treiber T, Ringle S, Treiber N, Flatley A, Feederle R, Bruckmann A and Meister G: Interactions, localization, and phosphorylation of the m6A generating METTL3-METTL14-WTAP complex. RNA. 24:499–512. 2018. View Article : Google Scholar : PubMed/NCBI | |
Tao Z, Zhao Y and Chen X: Role of methyltransferase-like enzyme 3 and methyltransferase-like enzyme 14 in urological cancers. PeerJ. 8:e95892020. View Article : Google Scholar : PubMed/NCBI | |
Cai J, Yang F, Zhan H, Situ J, Li W, Mao Y and Luo Y: RNA m6A methyltransferase METTL3 promotes the growth of prostate cancer by regulating hedgehog pathway. Onco Targets Ther. 12:9143–9152. 2019. View Article : Google Scholar : PubMed/NCBI | |
Ma XX, Cao ZG and Zhao SL: m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1. Eur Rev Med Pharmacol Sci. 24:3565–3571. 2020.PubMed/NCBI | |
Yuan Y, Du Y, Wang L and Liu X: The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation. J Cancer. 11:3588–3595. 2020. View Article : Google Scholar : PubMed/NCBI | |
Li J, Xie H, Ying Y, Chen H, Yan H, He L, Xu M, Xu X, Liang Z, Liu B, et al: YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Mol Cancer. 19:1522020. View Article : Google Scholar : PubMed/NCBI | |
Ma H, Zhang F, Zhong Q and Hou J: METTL3-mediated m6A modification of KIF3C-mRNA promotes prostate cancer progression and is negatively regulated by miR-320d. Aging (Albany NY). 13:22332–22344. 2021. View Article : Google Scholar : PubMed/NCBI | |
Chen Y, Pan C, Wang X, Xu D, Ma Y, Hu J, Chen P, Xiang Z, Rao Q and Han X: Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells. Theranostics. 11:7640–7657. 2021. View Article : Google Scholar : PubMed/NCBI | |
Li E, Wei B, Wang X and Kang R: METTL3 enhances cell adhesion through stabilizing integrin β1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma. Am J Cancer Res. 10:1012–1025. 2020.PubMed/NCBI | |
Wu LS, Qian JY, Wang M and Yang H: Identifying the role of Wilms tumor 1 associated protein in cancer prediction using integrative genomic analyses. Mol Med Rep. 14:2823–2831. 2016. View Article : Google Scholar : PubMed/NCBI | |
Piette ER and Moore JH: Identification of epistatic interactions between the human RNA demethylases FTO and ALKBH5 with gene set enrichment analysis informed by differential methylation. BMC Proc. 12 (Suppl 9):S592018. View Article : Google Scholar | |
Zou S, Toh JD, Wong KH, Gao YG, Hong W and Woon EC: N(6)-Methyladenosine: a conformational marker that regulates the substrate specificity of human demethylases FTO and ALKBH5. Sci Rep. 6:256772016. View Article : Google Scholar : PubMed/NCBI | |
Wu A, Cremaschi P, Wetterskog D, Conteduca V, Franceschini GM, Kleftogiannis D, Jayaram A, Sandhu S, Wong SQ, Benelli M, et al: Genome-wide plasma DNA methylation features of metastatic prostate cancer. J Clin Invest. 130:1991–2000. 2020. View Article : Google Scholar : PubMed/NCBI | |
Zhu K, Li Y and Xu Y: The FTO m6A demethylase inhibits the invasion and migration of prostate cancer cells by regulating total m6A levels. Life Sci. 271:1191802021. View Article : Google Scholar : PubMed/NCBI | |
Lewis SJ, Murad A, Chen L, Davey Smith G, Donovan J, Palmer T, Hamdy F, Neal D, Lane JA, Davis M, et al: Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One. 5:e134852010. View Article : Google Scholar : PubMed/NCBI | |
Khella MS, Salem AM, Abdel-Rahman O and Saad AS: The association between the FTO rs9939609 variant and malignant pleural mesothelioma risk: A case-control study. Genet Test Mol Biomarkers. 22:79–84. 2018. View Article : Google Scholar : PubMed/NCBI | |
Salgado-Montilla JL, Rodríguez-Cabán JL, Sánchez-García J, Sánchez-Ortiz R and Irizarry-Ramírez M: Impact of FTO SNPs rs9930506 and rs9939609 in prostate cancer severity in a cohort of puerto rican men. Arch Cancer Res. 5:1482017. View Article : Google Scholar : PubMed/NCBI | |
Li S and Cao L: Demethyltransferase FTO alpha-ketoglutarate dependent dioxygenase (FTO) regulates the proliferation, migration, invasion and tumor growth of prostate cancer by modulating the expression of melanocortin 4 receptor (MC4R). Bioengineered. 13:5598–5612. 2022. View Article : Google Scholar : PubMed/NCBI | |
Xu Y, Zhang W, Shen F, Yang X, Liu H, Dai S, Sun X, Huang J and Guo Q: YTH domain proteins: A family of m6A readers in cancer progression. Front Oncol. 11:6295602021. View Article : Google Scholar : PubMed/NCBI | |
Liu S, Li G, Li Q, Zhang Q, Zhuo L, Chen X, Zhai B, Sui X, Chen K and Xie T: The roles and mechanisms of YTH domain-containing proteins in cancer development and progression. Am J Cancer Res. 10:1068–1084. 2020.PubMed/NCBI | |
Müller S, Bley N, Busch B, Glaß M, Lederer M, Misiak C, Fuchs T, Wedler A, Haase J, Bertoldo JB, et al: The oncofetal RNA-binding protein IGF2BP1 is a druggable, post-transcriptional super-enhancer of E2F-driven gene expression in cancer. Nucleic Acids Res. 48:8576–8590. 2020. View Article : Google Scholar : PubMed/NCBI | |
Gruber AJ, Schmidt R, Ghosh S, Martin G, Gruber AR, van Nimwegen E and Zavolan M: Discovery of physiological and cancer-related regulators of 3′ UTR processing with KAPAC. Genome Biol. 19:442018. View Article : Google Scholar : PubMed/NCBI | |
Jiang M, Lu Y, Duan D, Wang H, Man G, Kang C, Abulimiti K and Li Y: Systematic investigation of mRNA N 6-methyladenosine machinery in primary prostate cancer. Dis Markers. 2020:88334382020. View Article : Google Scholar : PubMed/NCBI | |
Singh AN and Sharma N: Quantitative SWATH-based proteomic profiling for identification of mechanism-driven diagnostic biomarkers conferring in the progression of metastatic prostate cancer. Front Oncol. 10:4932020. View Article : Google Scholar : PubMed/NCBI | |
Torosyan Y, Dobi A, Glasman M, Mezhevaya K, Naga S, Huang W, Paweletz C, Leighton X, Pollard HB and Srivastava M: Role of multi-hnRNP nuclear complex in regulation of tumor suppressor ANXA7 in prostate cancer cells. Oncogene. 29:2457–2466. 2010. View Article : Google Scholar : PubMed/NCBI | |
Luxton HJ, Simpson BS, Mills IG, Brindle NR, Ahmed Z, Stavrinides V, Heavey S, Stamm S and Whitaker HC: The oncogene metadherin interacts with the known splicing proteins YTHDC1, Sam68 and T-STAR and plays a novel role in alternative mRNA splicing. Cancers (Basel). 11:12332019. View Article : Google Scholar : PubMed/NCBI | |
Li J, Yu W, Ge J, Zhang J, Wang Y, Wang P and Shi G: Targeting eIF3f suppresses the growth of prostate cancer cells by inhibiting Akt signaling. Onco Targets Ther. 13:3739–3750. 2020. View Article : Google Scholar : PubMed/NCBI | |
Saramäki O, Willi N, Bratt O, Gasser TC, Koivisto P, Nupponen NN, Bubendorf L and Visakorpi T: Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol. 159:2089–2094. 2001. View Article : Google Scholar : PubMed/NCBI | |
Savinainen KJ, Helenius MA, Lehtonen HJ and Visakorpi T: Overexpression of EIF3S3 promotes cancer cell growth. Prostate. 66:1144–1150. 2006. View Article : Google Scholar : PubMed/NCBI | |
Savinainen KJ, Linja MJ, Saramäki OR, Tammela TL, Chang GT, Brinkmann AO and Visakorpi T: Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer. 90:1041–1046. 2004. View Article : Google Scholar : PubMed/NCBI | |
Zhang X, Wang D, Liu B, Jin X, Wang X, Pan J, Tu W and Shao Y: IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way. J Exp Clin Cancer Res. 39:1902020. View Article : Google Scholar : PubMed/NCBI | |
Du C, Lv C, Feng Y and Yu S: Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. J Exp Clin Cancer Res. 39:2232020. View Article : Google Scholar : PubMed/NCBI | |
Li J, Meng S, Xu M, Wang S, He L, Xu X, Wang X and Xie L: Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels. Oncotarget. 9:3752–3764. 2018. View Article : Google Scholar : PubMed/NCBI | |
Gao Y, Teng J, Hong Y, Qu F, Ren J, Li L, Pan X, Chen L, Yin L, Xu D and Cui X: The oncogenic role of EIF3D is associated with increased cell cycle progression and motility in prostate cancer. Med Oncol. 32:5182015. View Article : Google Scholar : PubMed/NCBI | |
Zhang L, Smit-McBride Z, Pan X, Rheinhardt J and Hershey JW: An oncogenic role for the phosphorylated h-subunit of human translation initiation factor eIF3. J Biol Chem. 283:24047–24060. 2008. View Article : Google Scholar : PubMed/NCBI | |
Kawakami Y, Kubota N, Ekuni N, Suzuki-Yamamoto T, Kimoto M, Yamashita H, Tsuji H, Yoshimoto T, Jisaka M, Tanaka J, et al: Tumor-suppressive lipoxygenases inhibit the expression of c-myc mRNA coding region determinant-binding protein/insulin-like growth factor II mRNA-binding protein 1 in human prostate carcinoma PC-3 cells. Biosci Biotechnol Biochem. 73:1811–1817. 2009. View Article : Google Scholar : PubMed/NCBI | |
Wang H, Ru Y, Sanchez-Carbayo M, Wang X, Kieft JS and Theodorescu D: Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clin Cancer Res. 19:2850–2860. 2013. View Article : Google Scholar : PubMed/NCBI | |
Xiang P, Sun Y, Fang Z, Yan K and Fan Y: Eukaryotic translation initiation factor 3 subunit b is a novel oncogenic factor in prostate cancer. Mamm Genome. 31:197–204. 2020. View Article : Google Scholar : PubMed/NCBI | |
Hu J, Luo H, Xu Y, Luo G, Xu S, Zhu J, Song D, Sun Z and Kuang Y: The prognostic significance of EIF3C gene during the tumorigenesis of prostate cancer. Cancer Invest. 37:199–208. 2019. View Article : Google Scholar : PubMed/NCBI | |
Hershey JW: The role of eIF3 and its individual subunits in cancer. Biochim Biophys Acta. 1849:792–800. 2015. View Article : Google Scholar : PubMed/NCBI | |
Cui L, Liu M, Lai S, Hou H, Diao T, Zhang D, Wang M, Zhang Y and Wang J: Androgen upregulates the palmitoylation of eIF3L in human prostate LNCaP cells. Onco Targets Ther. 12:4451–4459. 2019. View Article : Google Scholar : PubMed/NCBI | |
Chromecki TF, Cha EK, Pummer K, Scherr DS, Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz PI and Shariat SF: Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. BJU Int. 110:63–68. 2012. View Article : Google Scholar : PubMed/NCBI | |
Cheng Y, Li L, Qin Z, Li X and Qi F: Identification of castration-resistant prostate cancer-related hub genes using weighted gene co-expression network analysis. J Cell Mol Med. 24:8006–8017. 2020. View Article : Google Scholar : PubMed/NCBI | |
Stockley J, Villasevil ME, Nixon C, Ahmad I, Leung HY and Rajan P: The RNA-binding protein hnRNPA2 regulates β-catenin protein expression and is overexpressed in prostate cancer. RNA Biol. 11:755–765. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lin VC, Kuo PT, Lin YC, Chen Y, Hseu YC, Yang HL, Kao JY, Ho CT and Way TD: Penta-O-galloyl-β-D-glucose suppresses EGF-induced eIF3i expression through inhibition of the PI3K/AKT/mTOR pathway in prostate cancer cells. J Agric Food Chem. 62:8990–8996. 2014. View Article : Google Scholar : PubMed/NCBI | |
Xie C, Li Y, Li Q, Chen Y, Yao J, Yin G, Bi Q, O'Keefe RJ, Schwarz EM and Tyler W: Increased insulin mRNA binding protein-3 expression correlates with vascular enhancement of renal cell carcinoma by intravenous contrast-CT and is associated with bone metastasis. J Bone Oncol. 4:69–76. 2015. View Article : Google Scholar : PubMed/NCBI | |
Yu YZ, Lv DJ, Wang C, Song XL, Xie T, Wang T, Li ZM, Guo JD, Fu DJ, Li KJ, et al: Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p. Mol Cancer. 21:122022. View Article : Google Scholar : PubMed/NCBI | |
Pin E, Henjes F, Hong MG, Wiklund F, Magnusson P, Bjartell A, Uhlén M, Nilsson P and Schwenk JM: Identification of a novel autoimmune peptide epitope of prostein in prostate cancer. J Proteome Res. 16:204–216. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wang J, Lin H, Zhou M, Xiang Q, Deng Y, Luo L, Liu Y, Zhu Z and Zhao Z: The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer. Future Oncol. 16:2421–2432. 2020. View Article : Google Scholar : PubMed/NCBI |